- Home
- PR vs ROIV Comparison
PR vs ROIV Comparison
Compare PR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PR | ROIV |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6B | 20.7B |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PR | ROIV |
|---|---|---|
| Price | $20.70 | $29.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 9 |
| Target Price | $22.35 | ★ $28.94 |
| AVG Volume (30 Days) | ★ 12.8M | 4.5M |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $5,065,211,000.00 | $29,053,000.00 |
| Revenue This Year | $20.94 | N/A |
| Revenue Next Year | $7.51 | $744.61 |
| P/E Ratio | $404.70 | ★ N/A |
| Revenue Growth | ★ 1.29 | N/A |
| 52 Week Low | $11.92 | $10.59 |
| 52 Week High | $22.68 | $30.33 |
Technical Indicators
Market Signals| Indicator | PR | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 51.39 | 59.74 |
| Support Level | $19.25 | $27.00 |
| Resistance Level | $21.99 | $30.26 |
| Average True Range (ATR) | 0.56 | 0.82 |
| MACD | -0.14 | 0.11 |
| Stochastic Oscillator | 36.16 | 90.00 |
Price Performance
Historical ComparisonAbout PR Permian Resources Corporation
Permian Resources Corp is an independent oil and natural gas company focused on generating outsized returns to stakeholders through the responsible acquisition, optimization, and development of oil and liquids-rich natural gas assets. The Company's assets and operations are concentrated in the core of the Permian Basin, and its properties consist of large, contiguous acreage blocks located in West Texas and New Mexico.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.